This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alkermes, Arena: Volume Movers

BOSTON ( TheStreet) -- Alkermes (ALKS - Get Report) shares were poised to rally Friday after the U.S. Food and Drug Administration recommended approval of the company's opioid dependence treatment, making it one of several stocks poised to move on above-average volume.

Alkermes was set to trade higher Friday after an FDA advisory committee voted 12 to 1 to recommend approval of Vivitrol, a treatment for patients who abuse opoids, such as heroin. The FDA has a target date of Oct. 12 to complete its review of the company's drug application for Vivitrol.

Shares of Alkermes were rallying by $1.38, or 9.7%, to $15.60 in the premarket session. The average daily share volume for Alkermes is 646,000.

On the other hand, Arena Pharmaceuticals (ARNA - Get Report) are dropping by $1.58, or 42.3%, to $2.16 in the premarket session after an FDA panel Thursday voted 9 to 5 against the company's weight-loss drug lorcaserin, highlighting safety concerns. The FDA will make its judgment on lorcaserin by Oct. 22. The average daily share volume for Arena is 10.9 million.

Crucell (CRXL) shares are surging by $11.31, or 55.1%, to $31.85 in the premarket session after Johnson & Johnson (JNJ - Get Report) said it is in advanced talks to acquire the rest of the Dutch biotech company in a $2.3 billion deal. J&J currently has a 17.9% stake in Crucell. The average daily share volume for Crucell is 47,000.

Transition Therapeutics (TTHI) shares are falling by 31 cents, or 8%, to $3.57 in the premarket session after the company said it has halted development of its experimental diabetes treatment TT-223 after it failed to meet efficacy endpoints in a study. The average daily share volume for Transition Therapeutics is 52,000.

-- Written by Robert Holmes in Boston.



>To contact the writer of this article, click here: Robert Holmes.

>To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet.

>To submit a news tip, send an email to: tips@thestreet.com.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ALKS $60.94 -0.05%
ARNA $4.31 -1.37%
JNJ $99.15 -1.44%
TTHI $6.80 -0.44%
YHOO $44.13 -0.69%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs